| pubmed-article:8058105 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C1527240 | lld:lifeskim |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C0087585 | lld:lifeskim |
| pubmed-article:8058105 | lifeskim:mentions | umls-concept:C0105592 | lld:lifeskim |
| pubmed-article:8058105 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8058105 | pubmed:dateCreated | 1994-9-14 | lld:pubmed |
| pubmed-article:8058105 | pubmed:abstractText | We have investigated the in vivo motor stimulating and gastroprokinetic properties of the azabicycloalkyl benzimidazolone derivative BIMU 1 (3-ethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-oxo-1H- benzimidazole-1-carboxamide hydrochloride) and its binding profile at 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors, in an attempt to assess the serotonergic mechanism underlying its prokinetic action. BIMU 1 dose-dependently (0.01-0.3 mg/kg i.v.) increased the motility of a denervated pouch of canine stomach. This excitatory action was sensitive to muscarinic blockade. A similar stimulatory effect was exerted by the benzamidic prokinetic agent cisapride (0.03-0.3 mg/kg i.v.) but not by the 5-HT3 receptor antagonist ondansetron (up to 1 mg/kg i.v.). The significance for propulsive efficacy of the motor stimulating activity of BIMU 1 was evaluated in a model of gastric emptying of liquids in the conscious dog. The emptying rate of a non-caloric liquid meal instilled through a gastric fistula was accelerated by both BIMU 1 (0.01-1 mg/kg i.v. and 0.1-3 mg/kg p.o.) and cisapride (0.03-1 mg/kg i.v. and 0.3-10 mg/kg p.o.). Ondansetron (1 mg/kg i.v.) did not show any effect. The activity of the 5-HT4 receptor antagonist DAU 6285 was evaluated in the gastric emptying model per se and in interaction experiments on the accelerating action of BIMU 1 (0.3 mg/kg i.v.).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:8058105 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8058105 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8058105 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8058105 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8058105 | pubmed:issn | 0028-1298 | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:LadinskyHH | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:DonettiAA | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:Schiantarelli... | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:RizziC ACA | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:SagradaAA | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:SchiavoneAA | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:CesanaRR | lld:pubmed |
| pubmed-article:8058105 | pubmed:author | pubmed-author:SchiaviG BGB | lld:pubmed |
| pubmed-article:8058105 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8058105 | pubmed:volume | 349 | lld:pubmed |
| pubmed-article:8058105 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8058105 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8058105 | pubmed:pagination | 338-45 | lld:pubmed |
| pubmed-article:8058105 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:meshHeading | pubmed-meshheading:8058105-... | lld:pubmed |
| pubmed-article:8058105 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8058105 | pubmed:articleTitle | Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. | lld:pubmed |
| pubmed-article:8058105 | pubmed:affiliation | Research and Development Division, Boehringer Ingelheim Italia, Milan. | lld:pubmed |
| pubmed-article:8058105 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8058105 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8058105 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8058105 | lld:pubmed |
